The economic consequences of breast cancer adjuvant hormonal treatments (Q37390094)

20 August 2017

The economic consequences of breast cancer adjuvant hormonal treatments (English)

1 reference

20 August 2017

Liliana E Pezzin

1

1 reference

PMCID

2763163

20 August 2017

Mallory B O'Niel

series ordinal

2

1 reference

PMCID

2763163

20 August 2017

Ann B Nattinger

series ordinal

3

1 reference

20 August 2017

1 November 2009

1 reference

Journal of General Internal Medicine

20 August 2017

1 reference

20 August 2017

24 Suppl 2

1 reference

20 August 2017

S446-50

1 reference

https://scigraph.springernature.com/pub.10.1007/s11606-009-1079-5

20 August 2017

0 references

cites work

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763163

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763163

The economics of cancer care in the UK.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763163

Estimating health care costs related to cancer treatment from SEER-Medicare data

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763163

Development of a comorbidity index using physician claims data

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763163

Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763163

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763163

The financial burden of cancer: estimates from a study of insured women with breast cancer.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763163

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763163

Race, socioeconomic status, and breast cancer treatment and survival

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763163

Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763163

The shape of age-incidence curves of female breast cancer by hormone-receptor status.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763163

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2763163

A comparative analysis of Medicaid long-term care policies and their effects on elderly dual enrollees

3 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19838848

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19838848

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11606-009-1079-5

1 reference

20 August 2017

1 reference

20 August 2017

1 reference

PMCID

2763163